Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy

References

• Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: the promising paths forward. Hepatology. 2022;76(1):233–250. doi:10.1002/hep.32314
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T. European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Kramvis A, Chang K-M, Dandri M, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022;19(11):727–745. doi:10.1038/s41575-022-00649-z
   PubMed Web of Science ®Google Scholar
• Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249–1262. doi:10.1016/j.jhep.2021.11.024
   PubMed Web of Science ®Google Scholar
• Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2):434. doi:10.3390/v14020434
   PubMed Web of Science ®Google Scholar
• Ye J, Chen J. Interferon and Hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364. doi:10.3389/fimmu.2021.733364
   PubMed Web of Science ®Google Scholar
• Tseng TC, Kao JH, Chen DS. Peginterferon alpha in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2014;14(7):995–1006. doi:10.1517/14712598.2014.907784
   PubMed Web of Science ®Google Scholar
• Graham H, Chandler DJ, Dunbar SA. The genesis and evolution of bead-based multiplexing. Methods. 2019;158:2–11. doi:10.1016/j.ymeth.2019.01.007
   PubMed Web of Science ®Google Scholar
• Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest. 2022;102(11):1170–1181. doi:10.1038/s41374-022-00830-7
   PubMed Web of Science ®Google Scholar
• Kong W, Li Y, Cheng S, et al. Luminex xMAP combined with Western blot improves HIV diagnostic sensitivity. J Virol Methods. 2016;227:1–5. doi:10.1016/j.jviromet.2015.10.007
   PubMed Web of Science ®Google Scholar
• Han ZQ, Huang T, Deng YZ, Zhu GZ. Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C. Int J Clin Exp Med. 2015;8(10):17995–18003.
   PubMed Web of Science ®Google Scholar
• Johansson S, Talloen W, Tuefferd M, et al. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Liver Int. 2016;36(3):344–352. doi:10.1111/liv.12932
   PubMed Web of Science ®Google Scholar
• Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2014;34(Suppl 1):112–119. doi:10.1111/liv.12400
   PubMed Web of Science ®Google Scholar
• Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis. 2016;20(4):645–665. doi:10.1016/j.cld.2016.06.002
   PubMed Web of Science ®Google Scholar
• Lynch HE, Sanchez AM, D’Souza MP, et al. Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. J Immunol Methods. 2014;409:62–71. doi:10.1016/j.jim.2014.04.011
   PubMed Web of Science ®Google Scholar
• Purohit S, Sharma A, She JX. Luminex and other multiplex high throughput technologies for the identification of, and host response to, environmental triggers of type 1 diabetes. Biomed Res Int. 2015;2015:326918. doi:10.1155/2015/326918
   PubMed Web of Science ®Google Scholar
• Ding Y, Zhang H, Chen H, et al. Association of immune response parameters with virological response in hepatitis C virus patients treated with pegylated consensus interferon. Int J Clin Pharmacol Ther. 2016;54(3):163–171. doi:10.5414/CP202439
   PubMed Web of Science ®Google Scholar
• Lu MY, Huang CI, Dai CY, et al. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep. 2016;6:22995. doi:10.1038/srep22995
   PubMed Web of Science ®Google Scholar
• Mihm U, Herrmann E, Sarrazin U, et al. Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol. 2004;40(5):845–852. doi:10.1016/j.jhep.2004.01.007
   PubMed Web of Science ®Google Scholar
• Fu WK, Cao J, Mi NN, et al. Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy. World J Clin Cases. 2020;8(11):2255–2265. doi:10.12998/wjcc.v8.i11.2255
   PubMed Web of Science ®Google Scholar
• Lee IC, Huang YH, Su CW, et al. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. PLoS One. 2013;8(10):e76798. doi:10.1371/journal.pone.0076798
   PubMed Web of Science ®Google Scholar
• Hou J, van Oord G, Groothuismink ZM, et al. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. J Virol. 2014;88(21):12254–12264. doi:10.1128/JVI.00775-14
   PubMed Web of Science ®Google Scholar
• Ma SW, Huang X, Li YY, et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol. 2012;56(4):775–781. doi:10.1016/j.jhep.2011.10.020
   PubMed Web of Science ®Google Scholar
• Li Y, Ma S, Tang L, et al. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology. 2013;58(4):1277–1286. doi:10.1002/hep.26489
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao C, Zhang L, et al. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antiviral Res. 2014;103:51–59. doi:10.1016/j.antiviral.2014.01.001
   PubMed Web of Science ®Google Scholar
• Yang K, Guan SH, Zhang H, et al. Enhanced levels of interleukin-8 are associated with hepatitis B virus infection and resistance to interferon-alpha therapy. Int J Mol Sci. 2014;15(11):21286–21298. doi:10.3390/ijms151121286
   PubMed Web of Science ®Google Scholar